Investors

Corporate Profile
Global Blood Therapeutics, Inc. (GBT) is a clinical-stage biopharmaceutical dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its late-stage product candidate, voxelotor (GBT440), for the treatment of sickle cell disease.
Stock Quote
GBT (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$42.66
Change (%) Stock is Down 4.02 (8.59%)
Volume4,168,638
Data as of 12/07/18 4:00 p.m. ET
Refresh quote
Featured Events
Webcast ImageWebcast
Regulatory Update for Voxelotor (Replay)
12/03/18 at 8:30 a.m. ET
Regulatory Update for Voxelotor
Monday, December 3, 2018 8:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
Global Blood Therapeutics Inc at the American Society of Hematology (ASH) 2018 Annual Meeting (Replay)
12/03/18 at 3:00 p.m. ET
Global Blood Therapeutics Inc at the American Society of Hematology (ASH) 2018 Annual Meeting
3:00 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Supporting Materials
Download Event Supporting Material ASH IR Event Presentation Slides
Corporate Presentation
Download Documentation ASH IR Event Presentation Slides
Download Documentation Corporate Presentation (November 2018)
Get help downloading or viewing the above file types
Recent NewsMore >>
DateTitle 
12/07/18Global Blood Therapeutics Prices a $150.0 Million Common Stock Public Offering
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (Nasdaq: GBT), a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities, today announced the pricing of its underwritten public offering of its common stock for gross proceeds of approximately $150.0 million, before deducting the underwriting discounts and commissions and other estimated off... 
Printer Friendly Version
12/06/18Global Blood Therapeutics Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (Nasdaq: GBT), a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities, today announced an agreement to sell $150.0 million in shares of its common stock in a registered underwritten public offering.  In addition, GBT has granted the underwriter a 30-day option to purchase up to $22.5 milli... 
Printer Friendly Version
12/04/18GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT or the Company) (NASDAQ: GBT) today announced that, on November 30, 2018, the compensation committee of the Company’s board of directors granted six new employees options to purchase an aggregate of 29,250 shares of the Company’s common stock with a per share exercise price of $31.54, the closing trading price on the grant date, and restricted stock units for an aggregate of 19,350 shares of the... 
Printer Friendly Version
12/03/18GBT Announces Positive 24-week Results from Phase 3 HOPE Study Demonstrating Clinically and Statistically Significant Improvements in Hemoglobin and Clinical Measures of Hemolysis and a Favorable Safety Profile
Interim Analysis of Data from 1500 mg Cohort of HOPE-KIDS 1 Study Consistent with Phase 3 HOPE- Results in Demonstrating Improvement in Hemoglobin and Clinical Measures of Hemolysis and Favorable Safety in Pediatric Patients Company to Host Investor Webcast Today, Monday, December 3, at 12:00 p.m. PT/3:00 p.m. ET, to Discuss Data SOUTH SAN FRANCISCO, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (Nasdaq: GBT) today announced updated efficacy and safety res... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Global Blood Therapeutics Inc posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.